Legend Biotech to Host Investor Conference Call on Third Quarter 2026 Results

What happened

Legend Biotech will host a conference call for investors at 8:00 a.m. ET on Tuesday, November 10, 2026, to review its third quarter 2026 financial results, with senior management providing an overview of quarterly performance.

Confirmed

Global impact / market context

The call gives investors a scheduled chance to hear management explain quarterly performance for a cell therapy company that develops and markets CARVYKTI with Johnson & Johnson, which can shape how shareholders judge revenue, costs, and cash needs.

Analyst inference

Legend Biotech describes itself as the largest standalone cell therapy company, with over 3,000 employees and a focus on CAR-T treatments for multiple myeloma. Its quarterly update may inform investor views on cell therapy companies and partnership-based drug commercialization.

Analyst inference

What to watch

1. The earnings press release and a replay of the webcast will be available in the Events and Presentations section of the Legend Biotech website about two hours after the call ends. Confirmed
2. Management is expected to provide an overview of quarterly financial performance on the call, so listeners may watch for details on revenue, costs, and spending plans tied to CARVYKTI. Proposed
3. Investors may watch whether commentary on CARVYKTI patient access and pipeline progress supports future capital spending needs, since expanded cell therapy development can require significant investment. Analyst inference

Evidence

• globenewswire.com